Mota Ventures to Replicate Successful U.S. Business Model for European Expansion of CBD Products, Immune Product Line and CBD Hand Sanitizer
Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTC:PEMTF) (the “Company”) is pleased to announce that it will be replicating its highly successful business plan and operations in the United States for expansion into the European market with its Sativida brand, acquired on March 26, 2020. Sativida is already one of the top search-ranked online retailers of CBD products in Spain and Mexico, with distribution channels in Spain, Portugal, Austria, Germany, France and the United Kingdom.
SUCCESSFUL USA BUSINESS MODEL EXPECTED TO SIGNIFICANTLY BOOST EUROPEAN OPERATIONS
Year-to-Date in 2020, Mota Ventures has announced the following significant milestones from its U.S. operations:
Interim Record Of 14,388 New Customers For April 1 – 23.
Record Of 20,959 New Customers For The Month Of March
Revenue Of $4,290,000 In March
Revenue Of $2,981,000 In February, Representing Growth Of 832% over same period last year
With the Company’s e-commerce capabilities and success in the U.S. market, combined with the current search engine strength and distribution channels of the Sativida brand, management is very confident in its prospects for rapid customer acquisition throughout Europe. This confidence is further supported by the Company’s successful launch of its immune support product line, as well as, the May 1 launch of its CBD based hand sanitizer, both of which will be included in the European expansion.
Much of the Company’s success in the U.S. market has been attributed to its’ strong supply chain, which has continued to operate uninterrupted despite global turmoil in 2020. The Company has been actively sourcing multiple CBD suppliers in Europe to ensure a supply chain that is as strong and consistent as the North America operations. The Company will be announcing further details of the European expansion in the coming weeks as they become available.
“We are excited to announce this European expansion plan. As the world economy begins to awaken, now is the opportune to utilize what we have accomplished in the United States and implement the same strategies in Europe. There are several key market opportunities we have identified in Europe and now is the time to capitalize. I look forward to announcing an official launch date in the coming weeks” stated Ryan Hoggan, CEO of the Company.
About Mota Ventures Corp.
Mota is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the U.S. through its Nature’s Exclusive brands. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.
Sativida is a producer and online retailer of CBD and branded CBD products in various jurisdictions in Europe, including Spain and the United Kingdom. Sativida currently develops and retails a vast range of organic CBD oils and cosmetics across Europe and is currently expanding its distribution network internationally.
This News Release is available on the company’s CEO Verified Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.
ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.
Chief Executive Officer
For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at IR@motaventuresco.com or www.motaventuresco.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.
Cautionary Note Regarding Forward-Looking Statement
All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the expansion of the immune product line in Europe, its plans to become a vertically integrated global CBD brand, its plans to cultivate and extract cannabis to produce CBD and high-quality value added CBD products in Latin America for distribution domestically and internationally and its plans to acquire revenue-producing CBD brands and operations in Europe and North America. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.
Both locations expand access to the state’s widest-ranging inventory of medical cannabis products for Central Florida patients
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of two brand-new Central Florida dispensaries. The new Clearwater and Tampa locations mark the Company’s 81 st and 82 nd nationwide, respectively, widening patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.
Philip Young, CEO and Director of Lobe, stated, “We are honored to welcome Bart to our Advisory Board. His first-hand experience on and off the field are tremendously valuable as we continue our research involving mild traumatic brain injuries and PTSD. These issues are prevalent in contact sports and we believe that athletes will play a prominent role in the continued acceptance of psychedelic medicines as legitimate treatment. We look forward to working with Bart as we seek to forge long-term strategic relationships.”
HempFusion Wellness Submits Novel Foods Dossier to the United Kingdom’s Regulatory Food Safety Agency
HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that it has submitted its dossier to the United Kingdom’s Regulatory Food Safety Agency (the “FSA”).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210303005322/en/